11
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Activin upregulation by NF-κB is required to maintain mesenchymal features of cancer stem-like cells in non-small cell lung cancer.

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Soluble growth factors and cytokines within the tumor microenvironment aid in the induction of the epithelial-to-mesenchymal transition (EMT). Although EMT promotes the development of cancer-initiating cells (CIC), cellular mechanisms by which cancer cells maintain mesenchymal phenotypes remain poorly understood. Work presented here indicates that induction of EMT stimulates non-small cell lung cancer (NSCLC) to secrete soluble factors that function in an autocrine fashion. Using gene expression profiling of all annotated and predicted secreted gene products, we find that NF-κB activity is required to upregulate INHBA/Activin, a morphogen in the TGFβ superfamily. INHBA is capable of inducing and maintaining mesenchymal phenotypes, including the expression of EMT master-switch regulators and self-renewal factors that sustain CIC phenotypes and promote lung metastasis. Our work demonstrates that INHBA mRNA and protein expression are commonly elevated in primary human NSCLC and provide evidence that INHBA is a critical autocrine factor that maintains mesenchymal properties of CICs to promote metastasis in NSCLC.

          Related collections

          Author and article information

          Journal
          Cancer Res.
          Cancer research
          1538-7445
          0008-5472
          Jan 15 2015
          : 75
          : 2
          Affiliations
          [1 ] Department of Biochemistry and Molecular Genetics, University of Virginia, Charlottesville, Virginia.
          [2 ] Department of Pathology, University of Virginia, Charlottesville, Virginia.
          [3 ] Department of Biochemistry and Molecular Genetics, University of Virginia, Charlottesville, Virginia. Department of Thoracic Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.
          [4 ] Department of Biochemistry and Molecular Genetics, University of Virginia, Charlottesville, Virginia. mwm3y@virginia.edu sb3de@Virginia.edu.
          Article
          0008-5472.CAN-13-2702 NIHMS646245
          10.1158/0008-5472.CAN-13-2702
          25432175
          6eaf4c65-f1e1-4e2f-a380-43bb8349a83e
          ©2014 American Association for Cancer Research.
          History

          Comments

          Comment on this article